Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Accured Expenses (2017 - 2025)

Cue Biopharma's Change in Accured Expenses history spans 9 years, with the latest figure at $352000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 125.81% year-over-year to $352000.0; the TTM value through Sep 2025 reached -$1.3 million, up 30.89%, while the annual FY2024 figure was -$1.2 million, 309.01% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $352000.0 at Cue Biopharma, up from -$2.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.0 million in Q3 2021 and bottomed at -$2.7 million in Q2 2025.
  • The 5-year median for Change in Accured Expenses is $27000.0 (2021), against an average of -$48276.2.
  • The largest annual shift saw Change in Accured Expenses surged 703.92% in 2023 before it crashed 320.47% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $630752.0 in 2021, then tumbled by 152.32% to -$330000.0 in 2022, then crashed by 198.48% to -$985000.0 in 2023, then surged by 70.46% to -$291000.0 in 2024, then soared by 220.96% to $352000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Change in Accured Expenses are $352000.0 (Q3 2025), -$2.7 million (Q2 2025), and $1.3 million (Q1 2025).